Email address,Domain name,Organization,Country,State,City,Postal code,Street,Confidence score,Type,Number of sources,Pattern,First name,Last name,Department,Position,Twitter handle,LinkedIn URL,Phone number,Source 1,Source 2,Source 3,Source 4,Source 5,Source 6,Source 7,Source 8,Source 9,Source 10,Source 11,Source 12,Source 13,Source 14,Source 15,Source 16,Source 17,Source 18,Source 19,Source 20,Source 21,Source 22,Source 23,Source 24,Source 25,Source 26,Source 27,Source 28,Source 29,Source 30
drugsafety@baxalta.com,baxalta.com,Baxalta,US,IL,,,,99,generic,2,{first}.{last},,,Legal,,,,,http://floweaseinfusionset.com/index.html,http://floweaseinfusionset.com,,,,,,,,,,,,,,,,,,,,,,,,,,,
clinicaltrialsdisclosure@baxalta.com,baxalta.com,Baxalta,US,IL,,,,98,generic,2,{first}.{last},,,,,,,,http://clinicaltrials.gov/ct2/show/results/nct02540356,http://clinicaltrials.gov/ct2/show/results/nct01757405,,,,,,,,,,,,,,,,,,,,,,,,,,,
lauren.denz@baxalta.com,baxalta.com,Baxalta,US,IL,,,,94,personal,5,{first}.{last},Lauren,Denz,,"","","",+1 224 940 3259,http://pharma-zeitung.de/baxalta-startet-als-zukunftsweisendes-globales-bio.7480.php,http://itespresso.fr/press-release/lancement-de-baxalta-un-leader-biopharmaceutique-mondial-dvou-aux-patients-atteints-de-maladies-orphelines-et-aux-besoins-mdicaux-non-combls,http://businesswire.com/news/home/20150701005350/en/baxalta-launches-global-biopharmaceutical-leader-dedicated-patients,http://businesswire.com/news/home/20160225005454/en/baxalta-announces-submission-supplemental-blas-expand-adynovate,http://qlifepro.com/press/20160404-19-26512/il-baxalta-incorporated-2,,,,,,,,,,,,,,,,,,,,,,,,
geoffrey.mogilner@baxalta.com,baxalta.com,Baxalta,US,IL,,,,93,personal,13,{first}.{last},Geoffrey,Mogilner,Operations & logistics,Manufacturing Operations,"","",+1 224 940 8619,http://businesswire.com/news/home/20160527005380/en,http://businesswire.com/news/home/20160524006203/en/thunderbolt-pharma-vitesse-biologics-company-acquires-rights,http://benzinga.com/pressreleases/16/05/b8041486/correcting-and-replacing-baxalta-shareholders-vote-to-approve-combinati,http://benzinga.com/pressreleases/16/05/b8027078/thunderbolt-pharma-inc-a-vitesse-biologics-company-acquires-rights-to-b,http://benzinga.com/pressreleases/16/05/b8034320/oncoresponse-secures-investment-from-baxalta,http://businesswire.com/news/home/20151217005076/en/baxalta-present-34th-annual-j.p.-morgan-healthcare,http://businesswire.com/news/home/20150804006834/en/baxalta-confirms-receipt-highly-conditional-unsolicited-proposal,http://businesswire.com/news/home/20160216005590/en/baxalta-posts-strong-fourth-quarter-2015-sales,http://presseportal.ch/de/pm/100059179/100782550,http://qlifepro.com/press/20151116-20-25409/il-baxalta-incorporated,http://prnewswire.com/news-releases/shire-to-combine-with-baxalta-creating-the-global-leader-in-rare-diseases-564834551.html,http://qlifepro.com/press/20160525-09-27177/il-baxalta-incorporated-3,http://prnewswire.co.uk/news-releases/shire-to-combine-with-baxalta-creating-the-global-leader-in-rare-diseases-564834701.html,,,,,,,,,,,,,,,,
daniela.riedl@baxalta.com,baxalta.com,Baxalta,US,IL,,,,92,personal,1,{first}.{last},Daniela,Riedl,,"","","","",http://oespid.org/deutsch/archiv/archiv-aktuell-2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,
mary.kay.ladone@baxalta.com,baxalta.com,Baxalta,US,IL,,,,90,personal,30,{first}.{last},,,Writing & communication,Journalist,,,,http://businesswire.com/news/home/20160531005265/en/baxalta-award-winning-photographer-debut-unique-exhibition-showcasing,http://itvibestech.com/news/detail/baxalta-and-symphogen-establish-strategic-collaboratiion-to-accelerate-inno,http://prnewswire.com/news-releases/baxaltas-adynovate-meets-endpoints-in-phase-3-study-of-hemophilia-a-patients-under-12-years-of-age-300195716.html,http://prnewswire.com/news-releases/shire-to-combine-with-baxalta-creating-the-global-leader-in-rare-diseases-564834551.html,http://ewhealthcare.com/news/detail/baxalta-and-symphogen-establish-strategic-collaboratiion-to-accelerate-inno,http://presseportal.ch/de/pm/100006541/100786811,http://prnewswire.com/news-releases/cti-biopharma-and-baxalta-complete-submission-of-new-drug-application-for-pacritinib-for-unmet-medical-need-in-myelofibrosis-300199090.html,http://stockguru.com/2016/01/11/coherus-and-baxalta-announce-chs-0214-investigational-etanercept-biosimilar-met-primary-efficacy-endpoint-in-phase-3-rheumatoid-arthritis-clinical-study-rapsody,http://businesswire.com/news/home/20160524006203/en/thunderbolt-pharma-vitesse-biologics-company-acquires-rights,http://businesswire.com/news/home/20151217005076/en/baxalta-present-34th-annual-j.p.-morgan-healthcare,http://symphogen.com/2016/01/baxalta-and-symphogen-establish-strategic-collaboration-to-accelerate-innovation-in-immuno-oncology,http://businesswire.com/news/home/20160225005157/en,http://prnewswire.co.uk/news-releases/shire-to-combine-with-baxalta-creating-the-global-leader-in-rare-diseases-564834701.html,http://prnewswire.co.uk/news-releases/shire-plc-shire-publication-of-circular-notice-of-general-meeting-and-prospectus-and-directorate-change-576066441.html,http://biospace.com/article/releases/baxalta-invests-1-6-billion-to-develop-car-t-therapies-with-precision-biosciences-,http://pm360online.com/coherus-and-baxalta-announce-chs-0214-investigational-etanercept-biosimilar-met-primary-efficacy-endpoint-in-phase-3-rheumatoid-arthritis-clinical-study-rapsody,http://benzinga.com/pressreleases/16/05/b8027078/thunderbolt-pharma-inc-a-vitesse-biologics-company-acquires-rights-to-b,http://presseportal.ch/de/pm/100059179/100782550,http://benzinga.com/pressreleases/16/05/b8041089/baxalta-shareholders-vote-to-approve-combination,http://qlifepro.com/press/20160525-09-27177/il-baxalta-incorporated-3,http://benzinga.com/pressreleases/16/05/b8028297/baxalta-reports-positive-phase-1-results-for-bax-930-investigational-re,http://outsourcedpharma.com/doc/shire-buys-baxalta-creating-giant-rare-disease-treatment-0001,http://biospace.com/article/baxalta-invests-1-6-billion-to-develop-car-t-therapies-with-precision-biosciences-,http://eldiariony.com/latinowire/baxalta-supports-research-to-raise-awareness-of-treatment-burden-on-patients-during-the-sixth-annual-world-primary-immunodeficiency-week,http://qlifepro.com/press/20151116-20-25409/il-baxalta-incorporated,http://qlifepro.com/press/20160404-19-26512/il-baxalta-incorporated-2,http://futurama5.rssing.com/chan-4084687/all_p38.html,http://laopinion.com/latinowire/baxaltas-adynovate-meets-endpoints-in-phase-3-study-of-hemophilia-a-patients-under-12-years-of-age,http://laraza.com/latinowire/baxaltas-adynovate-meets-endpoints-in-phase-3-study-of-hemophilia-a-patients-under-12-years-of-age,http://benzinga.com/pressreleases/15/11/n5979605/baxalta-to-advance-care-for-hemophilia-a-patients-with-fda-approval-of-
erik.drotos@baxalta.com,baxalta.com,Baxalta,US,IL,,,,89,personal,1,{first}.{last},Erik,Drotos,,,,,,http://wpbdf.org/wp-content/uploads/2014/11/hemogram2015fall.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
cornelia.kurtz@baxalta.com,baxalta.com,Baxalta,US,IL,,,,88,personal,1,{first}.{last},Cornelia,Kurtz,,,,,,http://vfa.de/download/forschung-fuer-das-leben-2015.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
werner.trebos@baxalta.com,baxalta.com,Baxalta,US,IL,,,,79,personal,1,{first}.{last},,,,,,,,http://fma.or.at/mitglieder/mitglieder-fma/alle,,,,,,,,,,,,,,,,,,,,,,,,,,,,
medinfo@baxalta.com,baxalta.com,Baxalta,US,IL,,,,79,generic,2,{first}.{last},,,Support,,,,,http://floweaseinfusionset.com/index.html,http://floweaseinfusionset.com,,,,,,,,,,,,,,,,,,,,,,,,,,,
servicecs.uk@baxalta.com,baxalta.com,Baxalta,US,IL,,,,78,generic,1,{first}.{last},,,Support,,,,,http://rupokworld.com/baxter-at-home-stockport/83385427,,,,,,,,,,,,,,,,,,,,,,,,,,,,
atmary.kay.ladone@baxalta.com,baxalta.com,Baxalta,US,IL,,,,77,personal,1,{first}.{last},,,,,,,,http://presseportal.ch/de/pm/100059179/100782550,,,,,,,,,,,,,,,,,,,,,,,,,,,,
medinfo.ca@baxalta.com,baxalta.com,Baxalta,US,IL,,,,76,generic,1,{first}.{last},,,,,,,,http://hema-quebec.qc.ca/userfiles/file/media/francais/hopitaux/15-026.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ludwig.hantson@baxalta.com,baxalta.com,Baxalta,US,IL,,,,75,personal,1,{first}.{last},,,,,,,,http://headquartersfact.com/baxalta,,,,,,,,,,,,,,,,,,,,,,,,,,,,
m.skardinskaite@baxalta.com,baxalta.com,Baxalta,US,IL,,,,74,personal,1,{first}.{last},,,,,,,,http://1182.ee/baxalta-estonia-ou,,,,,,,,,,,,,,,,,,,,,,,,,,,,
apotheke@baxalta.com,baxalta.com,Baxalta,US,IL,,,,10,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
